Transformed B-cell Non-hodgkin Lymphoma

• CLINICAL_TRIALS trial_result · 2026-03-16
  Clinical Trial Update: Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy [Phase 2]

  Phase 2 clinical trial evaluating a CD3xCD20 bispecific antibody for relapse/refractory B-cell non-Hodgkin lymphomas after CAR-T therapy has…

• CLINICAL_TRIALS trial_result · 2024-08-26
  Clinical Trial Update: Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

  Phase 2 study evaluating PolaR-ICE (polatuzumab vedotin, rituximab, ifosfamide, carboplatin, etoposide) as initial salvage therapy for relap…

• CLINICAL_TRIALS trial_result · 2023-06-07
  Clinical Trial Update: Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma [Phase 1, Phase 2]

  Phase 1/2 trial evaluating mogamulizumab in combination with pembrolizumab for relapsed or refractory diffuse large B-cell lymphoma and rela…